Literature DB >> 17991334

Future therapy for inflammatory bowel disease: should we rethink what we mean by "top down"?

Michael J G Farthing1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17991334     DOI： 10.1007/s11894-007-0041-0

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN： 1522-8037


× No keyword cloud information.
  9 in total

1.  Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease.

Authors:  G D'Haens; K Geboes; E Ponette; F Penninckx; P Rutgeerts
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

2.  Guidelines for the management of inflammatory bowel disease in adults.

Authors:  M J Carter; A J Lobo; S P L Travis
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

3.  Top-down versus step-up approaches to chronic inflammatory bowel disease: presumed innocent or presumed guilty.

Authors:  Stephen B Hanauer
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2005-11

Review 4.  Infliximab and azathioprine: bridge or parachute?

Authors:  Simon Travis
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

5.  European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

Authors:  S P L Travis; E F Stange; M Lémann; T Oresland; Y Chowers; A Forbes; G D'Haens; G Kitis; A Cortot; C Prantera; P Marteau; J-F Colombel; P Gionchetti; Y Bouhnik; E Tiret; J Kroesen; M Starlinger; N J Mortensen
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

Review 6.  Early or late guided missile in the treatment of Crohn's disease?

Authors:  R Caprilli; E Angelucci; A Cocco
Journal:  Dig Liver Dis       Date:  2005-10-05       Impact factor: 4.088

7.  A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease.

Authors:  J Markowitz; K Grancher; N Kohn; M Lesser; F Daum
Journal:  Gastroenterology       Date:  2000-10       Impact factor: 22.682

Review 8.  Review article: Infliximab therapy for inflammatory bowel disease--seven years on.

Authors:  P Rutgeerts; G Van Assche; S Vermeire
Journal:  Aliment Pharmacol Ther       Date:  2006-02-15       Impact factor: 8.171

9.  Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial.

Authors:  Marc Lémann; Jean-Yves Mary; Bernard Duclos; Michel Veyrac; Jean-Louis Dupas; Jean Charles Delchier; David Laharie; Jacques Moreau; Guillaume Cadiot; Laurence Picon; Arnaud Bourreille; Iradj Sobahni; Jean-Frederic Colombel
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.